Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, Terawaki Y, Fukuda T, Motonaga R, Tanabe M, Yanase T; Collaborators of Fukuoka Study of Ipragliflozin (FUSION) trial. Nomiyama T, et al. Among authors: terawaki y. Endocr J. 2018 Aug 27;65(8):859-867. doi: 10.1507/endocrj.EJ18-0022. Epub 2018 May 26. Endocr J. 2018. PMID: 29806620 Free article. Clinical Trial.
Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.
Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Terawaki Y, Nagasako H, Kudo T, Kodera T, Kobayashi K, Urata H, Yanase T; CHAT. Nomiyama T, et al. Among authors: terawaki y. Diabetes Res Clin Pract. 2012 Feb;95(2):e27-8. doi: 10.1016/j.diabres.2011.08.016. Epub 2011 Sep 6. Diabetes Res Clin Pract. 2012. PMID: 21899912 Clinical Trial. No abstract available.
The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis.
Terawaki Y, Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Tsutsumi Y, Murase K, Nagasako H, Hamanoue N, Sugimoto K, Takada A, Ito K, Abe Y, Sasatomi Y, Ogahara S, Nakashima H, Saito T, Yanase T. Terawaki Y, et al. Diabetol Metab Syndr. 2013 Feb 28;5(1):10. doi: 10.1186/1758-5996-5-10. Diabetol Metab Syndr. 2013. PMID: 23445717 Free PMC article.
Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Morinaga H, Tanaka T, Mizoguchi M, Nabeshima K, Tanaka M, Yanase T. Nomiyama T, et al. Among authors: terawaki y. Diabetes. 2014 Nov;63(11):3891-905. doi: 10.2337/db13-1169. Epub 2014 May 30. Diabetes. 2014. PMID: 24879833
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Tsutsumi Y, Nomiyama T, Kawanami T, Hamaguchi Y, Terawaki Y, Tanaka T, Murase K, Motonaga R, Tanabe M, Yanase T. Tsutsumi Y, et al. Among authors: terawaki y. PLoS One. 2015 Oct 6;10(10):e0139709. doi: 10.1371/journal.pone.0139709. eCollection 2015. PLoS One. 2015. PMID: 26439622 Free PMC article.
111 results